Live from the NASAC market site in the heart of New York City's Times Square, this is fast money.

Here's what's on tap tonight. Shetting pounds and not in a good way. Shares of Novo Nordisk seeing their lowest levels in nearly 18 months.

The headlines that keep sending the weight loss heavyweight lower and lower.

In a Bitcoin breakout, prices trading near all-time highs is present to let Trump promises

to make crypto a priority. What that means regulation of the next steps for the space? Plus,

could Intel be a takeover target this year? Just how much climate change has affected homeowners

insurance. And the last two traders revealed their 20-25 acronyms why Steve is putting on his

gloves and Courtney's going global.

I'm Melissa Lee, home to you live in Studio B at the NASDAQ on the desk tonight.

C. Grasso, Karen Feinerman, Courtney Garcia, and RBC's head of U.S. Equity Strategy, Lori Calvesina.

And we start off with the latest drag on drug makers, Novo Nordus, getting slammed after the

Centers for Medicare and Medicaid published, its list of 15 drugs subject to price negotiations for 2027, including Novo's

GLP-1 drugs, OZMPIC and Wagovi. That stock fell over 5 percent today, now trading at Lowe's

last scene in the summer of 2023. Eli Lilly shares falling in sympathy and broader concerns over pricing pressures in the

GLP 1 category.

Shares were down more than 4%.

Bringing its losses since Monday to 9%.

The company also trimmed 2025 guidance earlier in the week.

And another wrinkle for Novo, the company out with top line results of a trial that studied

a higher dose of Wagovi than is currently on the market.

Patients losing an average 20.7% of their body weight after 72 weeks.

That's still, though, slightly less than what patients see on existing doses of Eli Lilly Zepbound.

...